Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS
SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the
treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of
postmenopausal women.